131 related articles for article (PubMed ID: 24166988)
1. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
Kurmasheva RT; Reynolds CP; Kang MH; Allievi C; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 May; 61(5):922-4. PubMed ID: 24166988
[TBL] [Abstract][Full Text] [Related]
2. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
3. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA
Pediatr Blood Cancer; 2010 Dec; 55(6):1224-6. PubMed ID: 20979180
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.
Smith MA; Kang MH; Reynolds CP; Kurmasheva RT; Alexander D; Billups CA; Toretsky JA; Houghton PJ
Pediatr Blood Cancer; 2012 Oct; 59(4):753-5. PubMed ID: 22315235
[TBL] [Abstract][Full Text] [Related]
6. Initial testing of cisplatin by the pediatric preclinical testing program.
Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
[TBL] [Abstract][Full Text] [Related]
7. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
8. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
9. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
10. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
[TBL] [Abstract][Full Text] [Related]
12. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
Carol H; Gorlick R; Kolb EA; Morton CL; Manesh DM; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R
Pediatr Blood Cancer; 2014 Feb; 61(2):245-52. PubMed ID: 24038993
[TBL] [Abstract][Full Text] [Related]
13. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
[TBL] [Abstract][Full Text] [Related]
14. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
[TBL] [Abstract][Full Text] [Related]
15. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Garofalo C; Capristo M; Manara MC; Mancarella C; Landuzzi L; Belfiore A; Lollini PL; Picci P; Scotlandi K
PLoS One; 2013; 8(12):e83832. PubMed ID: 24391834
[TBL] [Abstract][Full Text] [Related]
16. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
17. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
18. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB
Pediatr Blood Cancer; 2013 Apr; 60(4):633-41. PubMed ID: 22753001
[TBL] [Abstract][Full Text] [Related]
19. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
